Document is current

Article History

Received: 28 October 2021

Accepted: 6 July 2022

First Online: 12 July 2022

Declarations

:

: The study was conducted in compliance with the International Conference on Harmonisation, Good Clinical Practice, and applicable regulatory requirements. The protocol was reviewed by an independent and appropriately constituted institutional review board/independent ethics committee. Informed consent was given by the patient for use of the data related to the excision for scientific research.

: Consent for publication is included in the informed consent form signed by all patients; the patient is now deceased.

: Nancy J Newman is a consultant for GenSight Biologics, Santhera Pharmaceuticals and Stealth BioTherapeutics, received research support from GenSight Biologics and Santhera Pharmaceuticals, served on the Data Safety Monitoring Board for Quark NAION study, and is a medical legal consultant. David J Calkins is a consultant for GenSight Biologics and Stuart Therapeutics. Patrick Yu-Wai-Man is a consultant for GenSight Biologics and Stealth BioTherapeutics and has received research support from GenSight Biologics and Santhera Pharmaceuticals. Valerio Carelli is a consultant for GenSight Biologics, Santhera Pharmaceuticals and Stealth BioTherapeutics and has received research support from Santhera Pharmaceuticals and Stealth BioTherapeutics. Magali Taiel is employed by GenSight Biologics, the sponsor of these studies. François Rugiero is an employee of Diamond Pharma Services, which received payment for non-clinical consulting. Pramila Singh, Alexandra Rogue and Philippe Ancian are employees of Charles River Laboratories, Evreux, France, which received payment for the conduct of this research from GenSight Biologics. José A Sahel is a cofounder and shareholder of GenSight Biologics and the patent coauthor on allotopic transport. The other authors have no conflicts of interest to declare that are relevant to the content of this article.